Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Cert. of designation
Director comp.
Scilex Holding Co Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/11/2023 8-K Quarterly results
10/06/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/05/2023 D Form D - Notice of Exempt Offering of Securities:
10/02/2023 8-K Quarterly results
09/29/2023 SC 13D SCLX Stock Acquisition JV LLC reports a 39.3% stake in Scilex Holding Company
09/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/28/2023 8-K Quarterly results
09/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/27/2023 8-K/A Entry into a Material Definitive Agreement  Interactive Data
09/27/2023 RW Form RW - Registration Withdrawal Request:
09/26/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/26/2023 SC 13D/A Sorrento Therapeutics, Inc. reports a 1.3% stake in Scilex Holding Company
09/26/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/26/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/26/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/26/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Senior Secured Promissory Note issued to Oramed Pharmaceuticals, Inc",
"Form of Scilex Holding Company Warrant to Purchase Common Stock",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of September 21, 2023, between Scilex Holding Company, a Delaware corporation , Oramed Pharmaceuticals, Inc., a Delaware corporation as the initial purchaser , and the Agent. WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Initial Purchaser, and the Initial Purchaser, desires to purchase from the Company, a promissory note and certain Warrants of the Company as more fully described in this Agreement; and WHEREAS, contemporaneous with the execution of this Agreement, the Initial Purchaser, Sorrento, Scintilla Pharmaceuticals, Inc. and the Company entered into t...",
"Registration Rights Agreement, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc",
"SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of September 21, 2023 , made by each of the signatories hereto in favor of the holders of that certain Senior Secured Promissory Note dated as of the date hereof due March 21, 2025 in the original aggregate principal amount of $101,875,000.00 and any Additional Notes issued by Scilex Holding Company, a Delaware corporation . W I T N E S S E T H: WHEREAS, pursuant to the Securities Purchase Agreement dated as of the date hereof, among Oramed Pharmaceuticals Inc. , Acquiom Agency Services LLC, as the collateral agent and the Company , the Company has agreed to sell and issue to the Inital Note Holder, and the Initial Note Holder has agreed to purchase from the Company the Note, subject to the terms and conditions set forth therein; and WHER...",
"Security Agreement, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC",
"Subordination Agreement, by and among eCapital Health Corp., Scilex Pharmaceuticals Inc. and Acquiom Agency Services LLC",
"Schedule I",
"Assignment, Assumption and Release Agreement, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc",
"Exhibit 10.8"
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/19/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
07/12/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
07/07/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy